News

LOCUST WALK NEWS Bausch Health to Acquire DURECT Corporation  DURECT’s lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough […]

LOCUST WALK NEWS Sun Pharma to Acquire Checkpoint Therapeutics Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment

LOCUST WALK NEWS CytoReason secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to scale its AI disease models

LOCUST WALK NEWS Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib Ascentage Pharma

LOCUST WALK NEWS Garuda Therapeutics Launches with $72 Million Series A Financing CAMBRIDGE, Mass.–(BUSINESS WIRE)–Garuda Therapeutics, a company creating off-the-shelf,

LOCUST WALK NEWS Locust Walk Acquisition Corp.’s Stockholders Approve Business Combination with eFFECTOR Therapeutics to Create Next-Generation Oncology Company Developing

LOCUST WALK NEWS eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company

LOCUST WALK NEWS Locust Walk Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on March 1,

LOCUST WALK NEWS Locust Walk Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option PHILADELPHIA